Top Markets
#1 ADO Protocol ADO Protocol +335.42%
#2 GoPlus Security GoPlus Security +41.13%
#3 Starpower Starpower +35.26%
#4 GAIB AID GAIB AID +24.67%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.65%
#6 The Black Bull The Black Bull +15.87%
#7 Nockchain Nockchain +14.43%
#8 Provenance Blockchain Provenance Blockchain +12.81%
#9 Casper Network Casper Network +12.45%
#10 DMT-NAT DMT-NAT +11.83%
Coin of the day
ADO Protocol ADO Protocol
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Rang în acțiuni #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Preț acțiune
$0.4264
Ultima sincronizare: 2022-09-14
Capitalizare de piață
$7.93M
Schimbare (1 zi)
-16.44%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Caladrius Biosciences, Inc. (CLBS)

Categorie

Healthcare
Venituri pentru Caladrius Biosciences, Inc. (CLBS)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Caladrius Biosciences, Inc., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Caladrius Biosciences, Inc. din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE